| Patients with t(12;22)/MN1-EVT6 oncogene, are frequently associated with myeloid neoplasms, poor response to chemotherapy, and inferior outcome. | neoplasm, |
| ETV6/NTRK3 fusion oncogene is associated with papillary thyroid carcinoma. | thyroid, |
| The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK/SAPK pathway. | None |
| The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells. | None |
| ETV6 functions with ARG as oncofusion protein and triggers the same signaling pathways associated with ABL oncogenes | None |
| the chromosomal translocation leads o formation of TEL/AML1 fusion oncogene and is most common genetic aberration in childhood B-cell precursor ALL. | None |
| A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation. | None |
| MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice. | None |
| Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein. | None |
| the amplification of ETV6 is a possible mechanism of leukeogenesis as oncogene | None |
| A subset of ALK-negative inflammatory myofibroblastic tumour (IMT) have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism. | None |
| we demonstrate the expression of the ETV6-NTRK3 fusion oncogene in a small subset of inflammatory myofibroblastic tumors | None |
| Haemopoietic transformation by the TEL/ABL oncogene. | None |